EyePoint Pharmaceuticals, Inc.(EYPT)

$14.96—

Chart

EyePoint Pharmaceuticals, Inc.(EYPT)

NASDAQ

$14.96—

Chart Studio

EYPT(EYPT)

EYPT

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.94

Aug 5, 2026 · Reports before open

Revenue Estimate

$383,000

FY2029E EPS$0.55

FY2030E EPS$2.53

Analyst Sentiment

Wall St. Consensus

Buy

18 analysts·Moderate coverage

Score

16 Buy (89%)2 Hold (11%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1689%

Hold

211%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$36.00

+143.2%

Consensus

$37.50

+153.4%

Bull

$39.00

+163.5%

12-Month Target Range18 analysts

$36.00$37.50$39.00

Current $14.80Consensus

Current Price

$14.80

Upside to Consensus

$22.70

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2844.61%

EPS—

FY2028

Rev+470.71%

EPS—

FY2029

Rev+96.13%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$51M	$291M	$571M	$863M
Low	$1M	$981,861	$291M	$17M	$25M
High	$3M	$101M	$291M	$1.13B	$1.70B
EBITDA Avg	$-2M	$-51M	$-291M	$-571M	$-863M
Low	$-3M	$-101M	$-291M	$-1.13B	$-1.70B
High	$-1M	$-981,861	$-291M	$-17M	$-25M
EBIT Avg	$-2M	$-51M	$-291M	$-571M	$-863M
Low	$-3M	$-101M	$-291M	$-1.13B	$-1.70B
High	$-1M	$-981,861	$-291M	$-17M	$-25M
Net Income Avg	$-267M	$-262M	$-190M	$40M	$186M
Low	$-310M	$-352M	$-216M	$-10M	$-49M
High	$-225M	$-86M	$51M	$91M	$420M
EPS Avg	$-3.53	$-2.81	$-1.31	$0.55	$2.53
Low	$-4.23	$-4.81	$-2.95	$-0.14	$-0.66
High	$-3.07	$-1.17	$0.70	$1.24	$5.74
Analysts (Rev / EPS)	9 / 8	8 / 7	9 / 7	4 / 2	4 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$338,583	$328,750	$200,000	$200,000	$300,000	$350,000
Low	$338,583	$328,750	$200,000	$200,000	$300,000	$350,000
High	$338,583	$328,750	$200,000	$200,000	$300,000	$350,000
EBITDA Avg	$-338,583	$-328,750	$-200,000	$-200,000	$-300,000	$-350,000
Low	$-338,583	$-328,750	$-200,000	$-200,000	$-300,000	$-350,000
High	$-338,583	$-328,750	$-200,000	$-200,000	$-300,000	$-350,000
EBIT Avg	$-338,583	$-328,750	$-200,000	$-200,000	$-300,000	$-350,000
Low	$-338,583	$-328,750	$-200,000	$-200,000	$-300,000	$-350,000
High	$-338,583	$-328,750	$-200,000	$-200,000	$-300,000	$-350,000
Net Income Avg	$-70M	$-70M	$-56M	$-55M	$-55M	$-55M
Low	$-86M	$-70M	$-56M	$-55M	$-55M	$-55M
High	$-49M	$-70M	$-56M	$-55M	$-55M	$-55M
EPS Avg	$-0.81	$-0.81	$-0.65	$-0.65	$-0.64	$-0.64
Low	$-1.00	$-0.81	$-0.65	$-0.65	$-0.64	$-0.64
High	$-0.56	$-0.81	$-0.65	$-0.65	$-0.64	$-0.64
Analysts (Rev / EPS)	6 / 6	5 / 4	3 / 2	3 / 2	3 / 2	3 / 2

Earnings Surprises

Recent Analyst Actions

Feb 19, 2026Mizuho Securities

EyePoint price target raised to $36 from $33 at Mizuho

Target:$36.00

+150.7%from $14.36

Feb 5, 2026RBC Capital

RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity'

Target:$39.00

+195.0%from $13.22

Oct 29, 2025Mizuho Securities

EyePoint price target raised to $33 from $28 at Mizuho

Target:$33.00

+169.4%from $12.25

Oct 20, 2025Mizuho Securities

Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Target:$28.00

+140.8%from $11.63

Nov 11, 2024H.C. Wainwright

EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright

Target:$22.00

+89.9%from $11.59

May 13, 2024H.C. Wainwright

EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at H.C. Wainwright

Target:$30.00

+146.5%from $12.17

May 7, 2024Mizuho Securities

EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at Mizuho

Target:$30.00

+167.9%from $11.20

Aug 4, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $25

Target:$25.00

+144.6%from $10.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance